Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02115529 | Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet | PHASE2 | COMPLETED | 331 | — | — | Apr 1, 2014 | Nov 1, 2015 | Dec 3, 2015 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Cesamet (nabilone) | ACTIVE_COMPARATOR | 0.5 mg capsule containing Cesamet (single dose) given preoperatively |
| Placebo | PLACEBO_COMPARATOR | identical capsule containing placebo (single dose) given preoperatively |
| Name | Type | Description |
|---|---|---|
| Nabilone | DRUG | Nabilone (0.5 mg) or placebo given preoperatively |
| Placebo | DRUG | Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively |
Inclusion Criteria: * Age 18 or older with an American Society of Anesthesiologists (ASA) physical status of I to III who are scheduled to undergo elective surgery under general anesthesia with pre-anesthesia consultation prior to surgery. * Subjects must be able to swallow study medication; * At a...